// App-Quantinova.ai

11515 : ALK-amplified circulating tumor cells as a surrogate marker for crizotinib benefit in ALK-rearranged non-small cell lung cancer patients.

Researchers

Presenter

  • Emma Pailler

Principal Investigators

  • Jordi Remon

  • Marianne Oulhen

  • Isabelle Borget

  • Kirsty Ross

  • Nathalie Auger

  • Fanny Billiot

  • Maud Ngocamus

  • David Planchard

  • Jean-Charles Soria

  • Francoise Farace

  • Benjamin Besse

Medical Centers

  • Inserm U981 Identification of Molecular Predictors and New Targets for Cancer Treatment, Villejuif, France

  • Gustave Roussy, Universite Paris-Saclay, Department of Biostatistics and Epidemiology, Villejuif, France

  • Gustave Roussy, Universite Paris-Saclay, Circulating Tumor Cells Translational Platform, CNRS UMS3655 INSERM US23 AMMICA, Villejuif, France

  • Gustave Roussy, Universite Paris-Saclay, Department of Biostatistics and Epidemiology, Villejuif, France

  • Inserm U981 Identification of Molecular Predictors and New Targets for Cancer Treatment, Villejuif, France

  • Gustave Roussy, Universite Paris-Saclay, Department of Biostatistics and Epidemiology, Villejuif, France

  • Department of Medicine. Gustave Roussy Cancer Campus, Universite Paris-Saclay, Villejuif, France

  • University of Paris Sud, Universite Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicetre, France

  • University of Paris Sud, Universite Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicetre, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

Drug/Treatment

  • Crizotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved